Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities

Amit K. Mittal, Ganapati V. Hegde, Patricia Aoun, Robert G Bociek, Bhavana J Dave, Avadhut D. Joshi, Warren G. Sanger, Dennis D. Weisenburger, Shantaram S Joshi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In B-cell chronic lymphocytic leukemia (CLL), Rai stage, immunoglobulin gene mutational status, chromosomal abnormalities, CD38 and ZAP-70 expression were used as prognostic markers. In this study, to understand the molecular basis of chromosomal abnormalities leading to tumor progression, 90 CLL patients were grouped into poor prognosis (with 11q deletion and trisomy 12) and good prognosis (with normal karyotype and 13q deletion) and their clinical outcome was assessed. Gene expression profiles of 35 CLL samples with poor outcome (11q deletion, n=9; trisomy 12, n=5) and good outcome (13q deletion, n=13; normal karyotype, n=8) were analyzed using oligonucleotide microarray. Significance analysis of microarray (SAM) identified 27 differentially expressed genes between these two subgroups with significant overexpression of ATF5 and underexpression of CDC16, PCDH8, SLAM, MNDA and ATF2 in CLL patients with poor outcome. ATF5 gene expression in CLL was further studied because of its role in the regulation of cell cycle progression/differentiation and apoptosis. The overexpression of ATF5 was confirmed by real-time PCR using 39 CLL samples from the poor and good outcome groups. ATF5 was significantly (p<0.001) overexpressed in the poor outcome group. Furthermore, ATF5 expression was significantly higher in the 11q deletion as well as trisomy 12 group alone compared to the 13q deletion and normal karyotype groups. ATF5 overexpression was also associated with significantly (p=0.04) shorter time to treatment. Similarly, expression of five underexpressed genes also correlated with longer time to treatment. Thus, this report demonstrates that ATF5 may be one of the key genes involved in increased proliferation and survival in 11q deletion or trisomy 12, whereas CD16, CD86, SLAM, MNDA and ATF2 may be involved in the decreased proliferation of CLL cells with 13q deletion or normal karyotype.

Original languageEnglish (US)
Pages (from-to)461-469
Number of pages9
JournalInternational journal of molecular medicine
Volume20
Issue number4
StatePublished - Oct 1 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Chromosome Aberrations
Karyotype
Trisomy
Genes
Immunoglobulin Genes
Microarray Analysis
Chromosome 11q trisomy
Oligonucleotide Array Sequence Analysis
Transcriptome
Real-Time Polymerase Chain Reaction
Cell Cycle
Apoptosis
Gene Expression
Survival
13q deletion syndrome
Therapeutics
Neoplasms

Keywords

  • 11q deletion
  • ATF5
  • Chromosomal abnormalities
  • Chronic lymphocytic leukemia
  • Trisomy 12

ASJC Scopus subject areas

  • Genetics

Cite this

Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. / Mittal, Amit K.; Hegde, Ganapati V.; Aoun, Patricia; Bociek, Robert G; Dave, Bhavana J; Joshi, Avadhut D.; Sanger, Warren G.; Weisenburger, Dennis D.; Joshi, Shantaram S.

In: International journal of molecular medicine, Vol. 20, No. 4, 01.10.2007, p. 461-469.

Research output: Contribution to journalArticle

Mittal, Amit K. ; Hegde, Ganapati V. ; Aoun, Patricia ; Bociek, Robert G ; Dave, Bhavana J ; Joshi, Avadhut D. ; Sanger, Warren G. ; Weisenburger, Dennis D. ; Joshi, Shantaram S. / Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. In: International journal of molecular medicine. 2007 ; Vol. 20, No. 4. pp. 461-469.
@article{0ec4b1b13d384d0d840b4520f7013f4c,
title = "Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities",
abstract = "In B-cell chronic lymphocytic leukemia (CLL), Rai stage, immunoglobulin gene mutational status, chromosomal abnormalities, CD38 and ZAP-70 expression were used as prognostic markers. In this study, to understand the molecular basis of chromosomal abnormalities leading to tumor progression, 90 CLL patients were grouped into poor prognosis (with 11q deletion and trisomy 12) and good prognosis (with normal karyotype and 13q deletion) and their clinical outcome was assessed. Gene expression profiles of 35 CLL samples with poor outcome (11q deletion, n=9; trisomy 12, n=5) and good outcome (13q deletion, n=13; normal karyotype, n=8) were analyzed using oligonucleotide microarray. Significance analysis of microarray (SAM) identified 27 differentially expressed genes between these two subgroups with significant overexpression of ATF5 and underexpression of CDC16, PCDH8, SLAM, MNDA and ATF2 in CLL patients with poor outcome. ATF5 gene expression in CLL was further studied because of its role in the regulation of cell cycle progression/differentiation and apoptosis. The overexpression of ATF5 was confirmed by real-time PCR using 39 CLL samples from the poor and good outcome groups. ATF5 was significantly (p<0.001) overexpressed in the poor outcome group. Furthermore, ATF5 expression was significantly higher in the 11q deletion as well as trisomy 12 group alone compared to the 13q deletion and normal karyotype groups. ATF5 overexpression was also associated with significantly (p=0.04) shorter time to treatment. Similarly, expression of five underexpressed genes also correlated with longer time to treatment. Thus, this report demonstrates that ATF5 may be one of the key genes involved in increased proliferation and survival in 11q deletion or trisomy 12, whereas CD16, CD86, SLAM, MNDA and ATF2 may be involved in the decreased proliferation of CLL cells with 13q deletion or normal karyotype.",
keywords = "11q deletion, ATF5, Chromosomal abnormalities, Chronic lymphocytic leukemia, Trisomy 12",
author = "Mittal, {Amit K.} and Hegde, {Ganapati V.} and Patricia Aoun and Bociek, {Robert G} and Dave, {Bhavana J} and Joshi, {Avadhut D.} and Sanger, {Warren G.} and Weisenburger, {Dennis D.} and Joshi, {Shantaram S}",
year = "2007",
month = "10",
day = "1",
language = "English (US)",
volume = "20",
pages = "461--469",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities

AU - Mittal, Amit K.

AU - Hegde, Ganapati V.

AU - Aoun, Patricia

AU - Bociek, Robert G

AU - Dave, Bhavana J

AU - Joshi, Avadhut D.

AU - Sanger, Warren G.

AU - Weisenburger, Dennis D.

AU - Joshi, Shantaram S

PY - 2007/10/1

Y1 - 2007/10/1

N2 - In B-cell chronic lymphocytic leukemia (CLL), Rai stage, immunoglobulin gene mutational status, chromosomal abnormalities, CD38 and ZAP-70 expression were used as prognostic markers. In this study, to understand the molecular basis of chromosomal abnormalities leading to tumor progression, 90 CLL patients were grouped into poor prognosis (with 11q deletion and trisomy 12) and good prognosis (with normal karyotype and 13q deletion) and their clinical outcome was assessed. Gene expression profiles of 35 CLL samples with poor outcome (11q deletion, n=9; trisomy 12, n=5) and good outcome (13q deletion, n=13; normal karyotype, n=8) were analyzed using oligonucleotide microarray. Significance analysis of microarray (SAM) identified 27 differentially expressed genes between these two subgroups with significant overexpression of ATF5 and underexpression of CDC16, PCDH8, SLAM, MNDA and ATF2 in CLL patients with poor outcome. ATF5 gene expression in CLL was further studied because of its role in the regulation of cell cycle progression/differentiation and apoptosis. The overexpression of ATF5 was confirmed by real-time PCR using 39 CLL samples from the poor and good outcome groups. ATF5 was significantly (p<0.001) overexpressed in the poor outcome group. Furthermore, ATF5 expression was significantly higher in the 11q deletion as well as trisomy 12 group alone compared to the 13q deletion and normal karyotype groups. ATF5 overexpression was also associated with significantly (p=0.04) shorter time to treatment. Similarly, expression of five underexpressed genes also correlated with longer time to treatment. Thus, this report demonstrates that ATF5 may be one of the key genes involved in increased proliferation and survival in 11q deletion or trisomy 12, whereas CD16, CD86, SLAM, MNDA and ATF2 may be involved in the decreased proliferation of CLL cells with 13q deletion or normal karyotype.

AB - In B-cell chronic lymphocytic leukemia (CLL), Rai stage, immunoglobulin gene mutational status, chromosomal abnormalities, CD38 and ZAP-70 expression were used as prognostic markers. In this study, to understand the molecular basis of chromosomal abnormalities leading to tumor progression, 90 CLL patients were grouped into poor prognosis (with 11q deletion and trisomy 12) and good prognosis (with normal karyotype and 13q deletion) and their clinical outcome was assessed. Gene expression profiles of 35 CLL samples with poor outcome (11q deletion, n=9; trisomy 12, n=5) and good outcome (13q deletion, n=13; normal karyotype, n=8) were analyzed using oligonucleotide microarray. Significance analysis of microarray (SAM) identified 27 differentially expressed genes between these two subgroups with significant overexpression of ATF5 and underexpression of CDC16, PCDH8, SLAM, MNDA and ATF2 in CLL patients with poor outcome. ATF5 gene expression in CLL was further studied because of its role in the regulation of cell cycle progression/differentiation and apoptosis. The overexpression of ATF5 was confirmed by real-time PCR using 39 CLL samples from the poor and good outcome groups. ATF5 was significantly (p<0.001) overexpressed in the poor outcome group. Furthermore, ATF5 expression was significantly higher in the 11q deletion as well as trisomy 12 group alone compared to the 13q deletion and normal karyotype groups. ATF5 overexpression was also associated with significantly (p=0.04) shorter time to treatment. Similarly, expression of five underexpressed genes also correlated with longer time to treatment. Thus, this report demonstrates that ATF5 may be one of the key genes involved in increased proliferation and survival in 11q deletion or trisomy 12, whereas CD16, CD86, SLAM, MNDA and ATF2 may be involved in the decreased proliferation of CLL cells with 13q deletion or normal karyotype.

KW - 11q deletion

KW - ATF5

KW - Chromosomal abnormalities

KW - Chronic lymphocytic leukemia

KW - Trisomy 12

UR - http://www.scopus.com/inward/record.url?scp=38449114255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449114255&partnerID=8YFLogxK

M3 - Article

C2 - 17786276

AN - SCOPUS:38449114255

VL - 20

SP - 461

EP - 469

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 4

ER -